Wegovy before and afters: what the trial evidence actually shows

You've found the images. Here is what the numbers behind them actually say.

Scroll any social platform for five minutes and you'll find before-and-after shots attributed to Wegovy. The honest starting point is that some of those results are broadly consistent with what clinical trials produced, and some are not. The STEP 1 trial followed 1,961 adults over 68 weeks and found that participants taking semaglutide 2.4mg lost an average of roughly 15% of their starting body weight, compared with about 2.4% in the placebo group. That is an average. For a person starting at 100 kg, 15% is 15 kg. For someone starting at 130 kg, it is nearly 20 kg. The photos you see online tend to feature the people whose results sit well above that average, which is human nature but not the full picture.

The timeline matters too. Most of the visible change in trials happened between months three and twelve, with weight continuing to fall more slowly after that. An image captioned "after 6 weeks" and one captioned "after 18 months" are telling very different stories, and without that context the comparison is essentially meaningless. If you want a grounded sense of how long Wegovy takes to work, the honest answer involves patience and a willingness to measure progress in months rather than weeks.

One more thing the photos rarely show: the lifestyle changes running alongside the medicine. Semaglutide reduces appetite significantly, but the trials paired it with a reduced-calorie diet and increased physical activity. That combination is what produces the numbers. The medicine creates the conditions; the habits consolidate them.

What a one-month result looks like (and why it is still early days

The most common question our prescribers hear in the first few weeks is some version of "is this working?" One month in, most people are still on 0.25mg or just moving to 0.5mg) early steps in the titration schedule that are designed primarily to let your body adjust, not to produce headline weight loss. Appetite suppression is often noticeable by week two or three, but the scales may not have moved dramatically yet.

Trial data broken down to the one-month point shows modest early losses, typically in the range of 1–3% of starting weight for most participants. That matters because it sets a realistic expectation: one-month Wegovy results are a starting point, not a finished story. People who abandon treatment at this stage because the visible change is small are stopping before the medicine has reached its working dose.

The titration schedule runs over roughly 16–20 weeks before reaching 2.4mg (or, for the newer 7.2mg pen, a longer path upward). Visible physical change tends to accelerate once the maintenance dose is established and sustained. Managing expectations in those early weeks is genuinely part of getting a good outcome, and it is a conversation worth having with your prescriber, not something to benchmark against a photo someone posted on the internet.

Men, women, and the variation in results people rarely talk about

Before-and-after images skew heavily toward one demographic. The clinical trial data is more balanced. The STEP 1 trial included participants across a range of ages, BMIs and backgrounds, and found the 15% average held broadly across groups, though there was meaningful variation within that.

Some research suggests men and women may experience different rates of early loss, with men sometimes seeing faster initial changes, though the longer-term averages converge. Results for men on Wegovy are shaped by the same core factors as anyone else: starting weight, adherence to lifestyle changes, and how long treatment continues. Higher starting BMI often correlates with higher absolute weight loss in kilograms, even if the percentage is similar.

Age, metabolic health, whether someone has type 2 diabetes (which tends to reduce the response somewhat, as seen across GLP-1 trials), and individual gut-hormone biology all play a role. None of that is visible in a before-and-after photo. Two people with identical images may have had completely different clinical journeys, and a third person with a less dramatic visual change may have improved their blood pressure and sleep quality substantially. The camera captures weight. It does not capture health.

For a fuller picture of the evidence base, the clinical results behind Wegovy page walks through the trial data in more detail, including what the STEP programme found across different populations.

The MHRA's higher-dose approval and what it adds to the picture

The standard before-and-after story for Wegovy was written at 2.4mg. That changed in early 2026. The MHRA approved a 7.2mg maintenance dose (and then, on 14 April 2026, approved a dedicated single-dose 7.2mg pen) for adults with a BMI of 30 or above. Trial data at the higher dose reported average weight loss of around 20.7% over 72 weeks, which moves the expected outcome meaningfully closer to what the tirzepatide trials produced.

That is a significant shift in what before-and-after results at the top of the Wegovy schedule may look like going forward. The NHS overview of weight management injections covers the licensed options in the UK, and the landscape has changed substantially since the original Wegovy approvals. Whether the 7.2mg dose is appropriate for any individual patient is a clinical decision, not one a photo can answer.

Wegovy is a prescription-only medicine, and a prescriber reviews every person's suitability before treatment starts. If you are considering it, the right starting point is a proper clinical assessment, not a comparison to someone else's transformation. You can read more about Wegovy and how it works, or explore what Wegovy costs privately in the UK before you start your consultation. When you are ready, check your eligibility through a free consultation with one of our GPhC-registered prescribers, reviewed the same day, dispatched the same day if approved, delivered the next working day in a plain DPD box with no branding on the outside.